Vet Pathol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Restucci, B.
Right arrow Articles by De Vico, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Restucci, B.
Right arrow Articles by De Vico, G.
Vet Pathol 39:488-493 (2002)
© 2002 American College of Veterinary Pathologists

Expression of Vascular Endothelial Growth Factor in Canine Mammary Tumors

B. Restucci, S. Papparella, P. Maiolino and G. De Vico

Dipartimento di Patologia e Sanità Animale, Settore Anatomia Patologica, Facoltà di Medicina Veterinaria, Università di Napoli, Napoli, Italia (BR, SP, PM); and Istituto di Patologia Generale e Anatomia Patologica, Facoltà di Medicina Veterinaria, Università di Messina, Messina, Italia (GDV)


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Vascular endothelial growth factor (VEGF) is a dimeric protein that stimulates angiogenesis in vitro and in vivo by inducing endothelial cell proliferation and migration. In this immunohistochemical study, VEGF-immunolabeled cells were counted in a series of 10 benign and 40 malignant canine mammary tumors. The morphologic pattern of VEGF positivity (intensity of immunolabeling and VEGF granule size and distribution) was also evaluated. A low number of cells weakly positive for VEGF with few and small granules polarized to the luminal pole was detected in benign neoplasms. In contrast, in malignancies a high number of VEGF-positive cells had strong immunolabeling, often with large granules found diffusely in the cytoplasm. This level of immunolabeling was more pronounced in the less differentiated, more malignant phenotypes (grade 3). Macrophages, which can synthesize VEGF, were strongly positive. Stromal and myoepithelial cells were negative. VEGF data were correlated statistically with intratumoral microvessel density (number of newly formed microvessels) and both measures were greater in less differentiated malignant neoplasms, demonstrating that angiogenesis and malignancy increase together. VEGF appears to be a powerful angiogenic factor in canine mammary tumors.

Key words: Angiogenesis; canine mammary neoplasms; intratumoral microvessel density; VEGF.

Angiogenesis, the formation of new vessels from the preexisting vascular bed, is a physiologic process that is tightly regulated by stimulatory and inhibitory factors that function in a delicate balance.8,10 In tumors, the balance falls in favor of stimulatory factors, and the angiogenesis increases. Among these factors, vascular endothelial growth factor (VEGF) is the most thoroughly investigated in human oncology.4,13,21,25,29 It is a dimeric protein that stimulates migration and proliferation of vascular endothelial cells, key steps in angiogenesis.5,7,15 It is produced by neoplastic cells, macrophages, plasma cells, and sometimes also by lymphocytes and exerts paracrine effects by binding specific tyrosinase receptors localized on vascular endothelial cells, but it may also exert autocrine effects by stimulating neoplastic cell growth.17

In many human malignant tumors, overexpression of VEGF has been correlated with metastasis,27 and experimental studies using animal models have demonstrated that the inhibition of VEGF production by administration of anti-VEGF antibodies was associated with a reduction of the neoplastic growth.12 Therefore, VEGF is considered an important angiogenic factor in human oncology.

Because this angiogenic factor is still poorly investigated in veterinary oncology,18 the aim of the present study was to evaluate VEGF expression in a series of canine mammary tumors and to correlate this expression with the differentiation grade and microvessel density of neoplasms.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Samples

Fifty samples of canine mammary tumors (10 benign and 40 malignant) were examined. Tumors were classified using The World Health Organization criteria9 (Table 1) and were graded as moderately to poorly differentiated (grades 1–3) by two independent observers. The parameters used were 1) extent of tubule formation (for tubular and papillary adenocarcinomas), 2) hyperchromatism and number of mitoses, and 3) irregularity of size, shape, and staining of nuclei.19


View this table:
[in this window]
[in a new window]
  		Table 1. WHO classification of canine mammary tumors used in this study.

 
Among the malignant tumors, two of 18 tubular adenocarcinomas, three of six solid carcinomas, two of three squamous cell carcinomas, and one of three malignant mixed tumors, all grade 3, had already metastasized to the inguinal lymph nodes at the time of diagnosis. Two of the three early metastatic solid carcinomas metastasized to the lung after two years. Three of 10 tubular adenocarcinomas (grade 2) and two of six solid carcinomas (grade 3) that had not metastasized at the time of diagnosis spread to lungs, liver, and bones after 2 years.

Immunohistochemistry

All samples were fixed in 10% neutral buffered formalin and embedded in paraffin. Sections 5 µm thick were deparaffinized in xylene, dehydrated in graded alcohols, and washed in 0.01 M phosphate-buffered saline (PBS), pH 7.2–7.4. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in absolute methanol for 30 minutes. Before the immunohistochemical procedure, samples in ethylenediamine tetraacetic acid were heated three times for 5 minutes each at 750 W in a microwave oven. The primary antibody was a monoclonal mouse anti-human VEGF Ab-3 (clone JH121, NeoMarkers).

The antibody was diluted 1:200 in Tris-HCl buffer containing 0.5% bovine serum albumin and 0.015 M sodium azide (Dako). The sections were incubated overnight at 4 C. The immunolabeling procedure included negative control sections incubated in PBS without primary antibody. Biotinylated anti-mouse, anti-rabbit, and anti-goat immunoglobulins (LSAB Kit; Dako) diluted in PBS were used as secondary antibodies; they were applied for 30 minutes. After washing in PBS, the sections were incubated in streptavidin conjugated to horseradish peroxidase in Tris-HCl buffer containing 0.015% sodium azide (LSAB Kit; Dako) for 30 minutes. To demonstrate the immunolabeling, 3,3'-diaminobenzidine tetrahydrochloride was used as a chromogen, and hematoxylin was used as a counterstain.

Scoring of immunoreactivity

A count of VEGF-positive cells was performed by two observers at 400x magnification (40x objective + 10x ocular). At least 20 fields per tumor were examined, and a minimum of 1,000 neoplastic cells were counted. The results were expressed as a percentage. VEGF intensity was scored as follows: + = strong; ± = weak. VEGF granule size was scored as SG (small granules) when the immunoreactivity was expressed by small cytoplasmic brown granules and LG (large granules) when the immunoreactivity was expressed by large cytoplasmic brown granules. VEGF distribution was also scored as P (polarized) when the VEGF granules were restricted to the luminal pole of neoplastic cells and C (cytoplasmic) when the VEGF granules were located diffusely in the cytoplasm. Microvessel density was assessed by image analysis system as previously described.23 Twenty fields per tumor were randomly chosen, and every immunolabeled intratumoral vessel was counted on a 400x field using an automated (Image Pro Plus 1) image analysis system (Sistema MONO; Immagini e Computer, Milan, Italy).

Statistical analysis

VEGF-positive cell number and microvessel density, expressed as means and SDs, were both compared with differentiation grade of mammary neoplasms by analysis of variance (ANOVA). VEGF-positive cell number and microvessel density were compared with each other among the benign mammary neoplasms and different malignant grades using the linear regression.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
In benign tumors (Table 2), neoplastic cells expressed weak, fine granular immunolabeling that was polarized to the luminal pole (Fig. 1). The percentage of positive cells ranged from 8.4% to 15.2% (9.7% ± 2.5%). In six of 14 grade 1 tumors (Table 3), neoplastic cells expressed strong VEGF immunolabeling (+); in the remaining eight samples, the VEGF intensity was weak (±). In most of grade 1 tumors, VEGF granules were small and polarized to the luminal cell pole (SG/P). Percentage of positive cells ranged from 11.3% to 28.1% (15.2% + 5.5%). Ten of 12 grade 2 tumors (Table 3) expressed strong VEGF immunolabeling (+). VEGF granules were small and polarized in six samples (SG/P) and large and diffuse in the cytoplasm in the others (LG/C) (Fig. 2). Percentage of positive cells ranged from 14.7% to 32.7% (23.2% ± 5.1%). Eleven of 14 grade 3 tumors (Table 3) expressed strong VEGF immunolabeling (+). VEGF granules were large and diffuse in the cell cytoplasms (LG/C) (Fig. 3). The percentage of positive cells ranged from 24.3% to 37.4% (33% ± 4.4%).


View this table:
[in this window]
[in a new window]
  		Table 2. VEGF expression in benign canine mammary tumors.

 


View larger version (168K):
[in this window]
[in a new window]
  		Fig. 1. Canine mammary fibroadenoma; tumor No. 9. Weak VEGF immunolabeling is seen in a few neoplastic cells showing small abluminal granules (SG/P) (arrows). Fig. 1a. HE. Bar = 10 µm. Fig. 1b. Streptavidin–biotin–peroxidase complex method. Bar = 10 µm.
Fig. 2. Canine grade 2 tubular adenocarcinoma; tumor No. 24. Neoplastic cells show strong VEGF immunolabeling expressed by small and polarized granules. Some neoplastic cells showing strong diffuse immunolabeling are also present (arrow).
Fig. 1a. HE. Bar = 10 µm.
Fig. 1b. Streptavidin–biotin–peroxidase complex method. Bar = 10 µm.

 

View this table:
[in this window]
[in a new window]
  		Table 3. VEGF expression in malignant canine mammary tumors.

 


View larger version (159K):
[in this window]
[in a new window]
  		Fig. 3. Canine grade 3 tubular adenocarcinoma; tumor No. 28. Many neoplastic cells show strong diffuse VEGF immunolabeling. Streptavidin–biotin–peroxidase complex method. Bar = 10 µm.

 
In many malignant neoplasms, strong and diffuse immunolabeling was expressed by neoplastic cells located near necrotic centers. Macrophages, which were present at the periphery and often infiltrated the neoplastic proliferations, expressed strong and diffuse immunolabeling and were used as positive controls. Stromal and myoepithelial cells were negative. The number of VEGF-positive cells was higher in malignant than in benign tumors (P < 0.0001); among the malignant tumors, the values increased progressively from grade 1 to 3 (P < 0.0001) (Table 4).


View this table:
[in this window]
[in a new window]
  		Table 4. Correlation of number of VEGE positive cells and microvessel density with differentiation grade of tumor.

 
Microvessel density was greater in malignant than in benign tumors (P < 0.0001), and less differentiated phenotypes had higher numbers of microvessels than did more differentiated malignancies (P < 0.0001).

VEGF-positive cells and microvessel density were correlated with each other for both benign and malignant tumors (r = 0.992) (Fig. 4).



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 4. Correlation of VEGF-positive cells with microvessel density for benign and malignant (grades G1–G3) canine mammary tumors.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In tumors, increased VEGF synthesis is considered one of the first expressions of the angiogenetic switch, which contributes to acquisition of malignant characteristics such as rapid growth and metastasis.3,10 In this study, an increase in VEGF production, as indicated by a high number of positive cells associated with a loss of VEGF granule polarization, was observed in malignant tumors, especially those that were less differentiated. Loss of polarization of VEGF granules, which was more evident in grade 2 and grade 3 tumors than in benign or grade 1 neoplasms, could be a consequence of the enhanced VEGF synthesis and VEGF accumulation in neoplastic cells. The increase in VEGF synthesis could be linked to the activation of oncogenes encoding VEGF6 or to the loss of suppressor genes encoding VEGF inhibitors.22

Upregulation of VEGF could be also linked to the hypoxic condition present in the necrotic compartments. VEGF expression is highest in tumors with significant necrosis.24 Hypoxia can increase transcription of the VEGF-encoding gene and can stabilize its mRNA product,11 which could explain the strong immunolabeling observed in neoplastic cells located near the necrotic regions of malignant tumors. The hypoxic response also could act synergistically with other tumor-related factors, including cytokines such as tumor necrosis factor {alpha} produced by macrophages and other inflammatory cells, to upregulate VEGF in neoplasms. In this regard, macrophages, which can also synthesize VEGF, could play an important role in VEGF-mediated angiogenesis.14,16

In this study, the upregulation of VEGF also was correlated with microvessel density, in agreement with results of some human studies.13,26,27

In a previous evaluation of mammary neoplastic vasculature,23 the values for microvessel areas and perimeters were lower in less differentiated malignant tumors than in more differentiated malignant and benign tumors. VEGF stimulates endothelial cell proliferation and migration, but many other angiogenic factors are necessary for mature, functioning new vessels. Therefore, in tumors, VEGF-induced endothelial cell proliferation may not be adequately balanced by other angiogenic factor synthesis. As a consequence, in malignant tumors, microvessels become aberrant, neoplastic cells outgrow the vascular oxygen supply, and the result is ischemic necrosis.1

Endothelial cell proliferation induced by VEGF promotes metastasis by 1) inducing formation of new vessels, 2) producing collagenase and other degradative enzymes that facilitate neoplastic cell escape from the mass into the vasculature,20 and 3) stimulating neoplastic cell growth.28 Therefore, the more VEGF, the more endothelial cells, and the greater the risk for tumor growth and dissemination. This proposed sequence of events provides a theoretical explanation for the success of VEGF inhibition in experimental tumor therapy.2,12 In this regard, canine mammary neoplasms may be useful models for therapeutic trials.


   Acknowledgments
 
This work was supported by grants from the Ministero della Ricerca Scientifica e Tecnologica 1997. We thank Mr. R. Ilsami for technical assistance.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Belien JAM, Van Diest PJ, Baak PA: Relationships between vascularization and proliferation in invasive breast cancer. J Pathol 189:309-318, 1999[CrossRef][Medline]
  2. Borgstrom P, Hillan KJ, Srirmarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralising antibodies. Novel concept of angiostatic therapy from intravital videomicroscopy. Cancer Res 56:4032-4039, 1996[Abstract/Free Full Text]
  3. Connolly DT, Heuvelman DM, Nelson DM, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgriber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478, 1989
  4. De Jong JS, Van Diest PJ, Van der Valk P, Baak JP: Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis. J Pathol 184:53-57, 1998[CrossRef][Medline]
  5. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995[Abstract]
  6. Ferrara N: Vascular endothelial growth factor. Trends Cardiovasc Med 3:244-250, 1993[CrossRef]
  7. Ferrara N, Davis-Smith T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997[Abstract/Free Full Text]
  8. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6, 1990[Free Full Text]
  9. Hampe JF, Misdorp W: Tumours and dysplasia of the mammary gland. Bull WHO 50:111-113, 1974[Medline]
  10. Hanahan D, Folkman J: Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996[CrossRef][Medline]
  11. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 25:19761-19766,
  12. Kim KJ, Winer J: Inhibition of vascular endothelial growth factor–induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993[CrossRef][Medline]
  13. Lee AHS, Dublin EA, Bobrow LG, Poulson R: Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol 185:394-401, 1998[CrossRef][Medline]
  14. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190:430-436, 2000[CrossRef][Medline]
  15. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara NM: Vascular endothelial growth factor as a secreted angiogenic mitogen. Science 246:1306-1309, 1992
  16. Lewis JS, Landers RJ, Underwood JCE, Harris AL, Lewis CE: Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 192:150-158, 2000[CrossRef][Medline]
  17. Lui B, Earl HM, Baban D: Melanoma cell lines express VEGF receptors KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 217:721-727, 1995[CrossRef][Medline]
  18. Maiolino P, De Vico G, Restucci B: Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. J Comp Pathol 123:141-145, 2000[CrossRef][Medline]
  19. Misdorp W: Histologic classification and further characterization of tumours in domestic animals. Adv Vet Sci Comp Med 20:191-221, 1976[Medline]
  20. Moscatelli D, Gross J, Rifkin D: Angiogenic factors stimulate plasminogen activator and collagenase production by capillary endothelial cell. J Cell Biol 91:120a, 1981
  21. Nicosia RF: What is the role of vascular endothelial growth factor–related molecules in tumor angiogenesis? Am J Pathol 153:11-16, 1998[Free Full Text]
  22. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994[CrossRef][Medline]
  23. Restucci B, De Vico G, Maiolino P: Evaluation of angiogenesis in canine mammary tumors by quantitative platelet endothelial cell adhesion molecule immunohistochemistry. Vet Pathol 37:297-301, 2000[Abstract/Free Full Text]
  24. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992[CrossRef][Medline]
  25. Stitt AW, Simpson AC, Boocock C, Gardiner TA, Murphy GM, Archer DB: Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol 186:306-312, 1998[CrossRef][Medline]
  26. Takahashi Y, Bucana CD, Cleary KR, Ellis LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J Cancer 79:34-38, 1998[CrossRef][Medline]
  27. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor KDR correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res 55:3964-3968, 1995[Abstract/Free Full Text]
  28. Weidner N: Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 184:119-122, 1998[CrossRef][Medline]
  29. Wynter CVA, Simms LA, Buttenshaw RL, Biden KG, Young J, Leggett BA, Conrad RJ, Schock EM, Jass JR, Pillay SP: Angiogenic factor VEGF is decreased in human colorectal neoplasms showing DNA microsatellite instability. J Pathol 189:319-325, 1999[CrossRef][Medline]
Request reprints from Dr. B. Restucci, Department of Pathology and Animal Health, Faculty of Veterinary Medicine, Via Veterinaria 1, 80137 Napes (Italy).





This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Restucci, B.
Right arrow Articles by De Vico, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Restucci, B.
Right arrow Articles by De Vico, G.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS